eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Sovereign Medical

Sovereign House , Miles Gray Road , Basildon , Essex , SS14 3FR
Telephone: +44 (0)1268 535 200
Fax: +44 (0)1268 535 299
Medical Information Direct Line: +44 (0)1268 823 049
Medical Information e-mail: medinfo@amdipharm.com
Medical Information Fax: +44 (0)1268 535 287

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 26/09/2007
SPC Diloxanide Tablets 500mg (Sovereign Medical)


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Diloxanide Tablets 500mg


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active ingredient

Quantity

Diloxanide Furoate

500 mg


Go to top of the page
3. PHARMACEUTICAL FORM

A flat, white tablet, scored and with a characteristic engraving E/F on one face.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the treatment of acute and chronic intestinal amoebiasis.


Go to top of the page
4.2 Posology and method of administration

Adults: One tablet three times daily for ten days.

Children: 20 mg/kg bodyweight daily in divided doses for ten days. Furamide is not suitable for use in children weighing less than 25 kg.

Elderly: There is no need for dosage reduction in the elderly.

If required, a second course of treatment may be prescribed.


Go to top of the page
4.3 Contraindications

Hypersensitivity to diloxanide furoate.


Go to top of the page
4.4 Special warnings and precautions for use

Keep all medicines out of the reach of children.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

No clinically-significant drug interactions known.


Go to top of the page
4.6 Pregnancy and lactation

The safety of Furamide during pregnancy and lactation has not been established and use during these periods should therefore be avoided.


Go to top of the page
4.7 Effects on ability to drive and use machines

No adverse effects known.


Go to top of the page
4.8 Undesirable effects

No serious side effects have been reported and the bacterial flora of the gut is not upset. Flatulence sometimes occurs but may usually be disregarded. Occasionally, vomiting, pruritus and urticaria may occur.


Go to top of the page
4.9 Overdose

Furamide tablets are unlikely to constitute a hazard in overdosage. In severe overdosage, early gastric lavage is recommended. There is no specific antidote. Treatment should be symptomatic and supportive.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Diloxanide furoate is a luminal amoebicide acting principally in the bowel lumen, although its mode of action is not known.


Go to top of the page
5.2 Pharmacokinetic properties

In the gut, diloxanide furoate is largely, if not wholly, hydrolysed into diloxanide and furoic acid under the combined action of bacterial and gut esterases. After absorption, diloxanide is very rapidly conjugated to form a glucuronide. In circulating blood, it is present to about 99% as a glucuronide and 1% as free diloxanide. Diloxanide is predominantly excreted in the urine. It is believed that the unabsorbed diloxanide is the active anti-amoebic substance, up to 10% remaining in the gut which is subsequently excreted as diloxanide in the faeces.


Go to top of the page
5.3 Preclinical safety data

Not applicable.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Maize starch, pregelatinized maize starch, dried maize starch, magnesium stearate, purified water.


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

36 months.


Go to top of the page
6.4 Special precautions for storage

None.


Go to top of the page
6.5 Nature and contents of container

A white aluminium tube with a polythene foam disc and a white aluminium screw cap with flowed-in PVC. Pack size: 15 tablets.

A white polythene cylindrical bottle and white polypropylene screw cap fitted with a waxed aluminium-faced pulpboard liner. Pack size: 30 tablets.

A rectangular amber-glass bottle with a white tin-plate screw cap fitted with a waxed aluminium-faced pulpboard liner. Pack size: 250 tablets.

A white polythene cylindrical bottle and white polypropylene screw cap fitted with a waxed aluminium-faced pulpboard liner. Pack size: 250 tablets.


Go to top of the page
6.6 Special precautions for disposal and other handling

Not applicable.


Go to top of the page
Administrative Data

Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Waymade PLC

Sovereign House

Miles Gray Road

Basildon, Essex, SS14 3FR

United Kingdom


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 06464/0900


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

17 November 1999


Go to top of the page
10. DATE OF REVISION OF THE TEXT

29 February 2000


Go to top of the page
Legal Category

POM



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/10787/SPC/


Active Ingredients/Generics

 
   diloxanide furoate